Pathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinoma.
Abhishek TripathiCatherine M TangenMelissa PletsXiaochen LiMaria TretiakovaPeter A HumphreyAdebowale AdeniranPedro C BarataShuchi GulatiCristiane Decat BergerotDeepak K PruthiIan M ThompsonPrimo N LaraSeth P LernerSumanta K PalBrian M ShuchPublished in: BJU international (2024)
In this study, categorising papillary renal cell carcinoma into type 1 or 2 subtypes showed limited concordance between central and local pathological review and did not enrich for patients more likely to benefit from cabozantinib in the S1500 PAPMET trial.